A Phase 1 interventional study of Leucostim® and Neupogen® in Leucocytosis, sponsored by Biocad. Completed. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-12-19.
Sponsored by Biocad · Phase 1, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
BCD-002-1 is 1 phase clinical trial to evaluate pharmacokinetics, pharmacodynamics and safety of single-injection of Leucostim® to healthy volunteers compared to Neupogen®
Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Healthy volunteers in this group will receive single subcutaneous injection Leucostim® on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
Biological: Leucostim® · Biological: Neupogen®
Healthy volunteers in this group will receive single subcutaneous injection Neupogen®, on Day 1 followed by single subcutaneous injection Leucostim® on Day 29.
Biological: Leucostim® · Biological: Neupogen®
Healthy volunteers in this group will receive single intravenous injection Leucostim® on Day 1 followed by single intravenous injection Leucostim® on Day 29.
Biological: Leucostim® · Biological: Neupogen®
Healthy volunteers in this group will receive single intravenous injection Neupogen® on Day 1 followed by single subcutaneous intravenous Leucostim® on Day 29.
Biological: Leucostim® · Biological: Neupogen®
Leucostim® is filgrastim biosimilar.
Also known as: filgrastim
Also known as: filgrastim
AUC (0-48 Hours)
Area Under Curve (AUC) "concentration - time" from the moment of filgrastim injection to 48 hours
Time frame: 0 to 48 hours post-dose
Cmax After Subcutaneous Injection
Maximal concentration of filgrastim after subcutaneous injection of filgrastim
Time frame: 0 to 48 hours post-dose
Cmax After Intravenous Injection
Maximal concentration of filgrastim after intravenous injection of filgrastim
Time frame: 0 to 48 hours post-dose
Tmax After Injection
Time after single injection to reach maximal concentration of filgrastim
Time frame: 0 to 48 hours post-dose
Т½
Half-life of filgrastim after single injection of filgrastim
Time frame: 0 to 48 hours post-dose
Kel
The elimination rate constant after single injection of filgrastim
Time frame: 0 to 48 hours post-dose
Clearance
Clearance of filgrastim after single injection
Time frame: 0 to 48 hours post-dose
ANC-AUEC (0-336 Hours)
Area Under Effect Curve (AUEC) "effect - time" from the moment of filgrastim injection to 336 hours based on absolute neutrophil count (ANC)
Time frame: 0 to 336 hours post-dose
ANC-Emax
Maximal absolute neutrophil count after single filgrastim injection
Time frame: 0 to 336 hours post-dose
CD34-AUEC (0-336 Hours)
Area Under Effect Curve (AUEC) "effect - time" from the moment of filgrastim injection to 336 hours based on CD-34 cells count (CD34)
Time frame: 0 to 336 hours post-dose
CD34-Emax
Maximal absolute count of CD34-cells after single filgrastim injection
Time frame: 0 to 336 hours post-dose
Overall Frequency of Serious Adverse Events (SAE)
Time frame: 0 to 336 hours post-dose
Overall Frequency of Adverse Events (AE)
Time frame: 0 to 336 hours post-dose
Frequency of Local Reactions
Time frame: 0 to 336 hours post-dose
Frequency of AE/SAE 3-4 Grade CTCAE 4.03
Grading scale of CTCAE 4.03 Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL (activities of daily living). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.
Time frame: 0 to 336 hours post-dose
Frequency of Preliminary Withdrawal Due to AE/SAE
Time frame: 0 to 336 hours post-dose
Proportion of Patients With Binding or Neutralizing Antibodies to Filgrastim
Proportion of patients who had developed binding or neutralizing antibodies to filgrastim after single injection.
Time frame: 0 to 336 hours post-dose
| Milestone | Leucostim® --> Neupogen®, Subcutaneous Injections | Neupogen® --> Leucostim®, Subcutaneous Injections | Leucostim® --> Neupogen®, Intravenous Injections | Neupogen® --> Leucostim®, Intravenous Injections |
|---|---|---|---|---|
| Started | 18 | 18 | 12 | 12 |
| Completed | 18 | 18 | 11 | 12 |
| Not completed | 0 | 0 | 1 | 0 |
Area Under Curve (AUC) "concentration - time" from the moment of filgrastim injection to 48 hours
| picogram per ml / hour | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| AUC (0-48 Hours) | 168603.588 ± 47721.48 | 181152 ± 54706.439 | 411826.811 ± 204285.095 | 427355.99 ± 170878.6 |
Maximal concentration of filgrastim after subcutaneous injection of filgrastim
| picogram per ml | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections |
|---|---|---|
| Cmax After Subcutaneous Injection | 21605.163 ± 5247.467 | 23389.559 ± 7549.536 |
Maximal concentration of filgrastim after intravenous injection of filgrastim
| picogram per ml | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|
| Cmax After Intravenous Injection | 79751.577 ± 24810.907 | 90796.227 ± 25925.283 |
Time after single injection to reach maximal concentration of filgrastim
| hours | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| Tmax After Injection | 4 (4 to 4) | 4 (4 to 6) | 0.5 (0.5 to 2) | 0.5 (0.5 to 0.5) |
Half-life of filgrastim after single injection of filgrastim
| hours | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| Т½ | 4,386 (3,889 to 4,914) | 4,307 (4,025 to 4,757) | 2,746 (2,178 to 2,951) | 2,549 (2,079 to 3,136) |
The elimination rate constant after single injection of filgrastim
| hour-1 | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| Kel | 0.158 (0.141 to 0.173) | 0.161 (0.145 to 0.17) | 0.252 (0.173 to 0.318) | 0.272 (0.219 to 0.316) |
Clearance of filgrastim after single injection
| ml per hour | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| Clearance | 2048.087 (1893.882 to 2518.863) | 1981.707 (1581.655 to 2439.947) | 965.938 (595.547 to 1055.471) | 830.442 (724.578 to 941.928) |
Area Under Effect Curve (AUEC) "effect - time" from the moment of filgrastim injection to 336 hours based on absolute neutrophil count (ANC)
| cells х10^9 per liter/hour | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| ANC-AUEC (0-336 Hours) | 1924.284 ± 326.455 | 1933.358 ± 309.533 | 1860.922 ± 372.861 | 1895.82 ± 426.826 |
Maximal absolute neutrophil count after single filgrastim injection
| cells х10^9 per liter | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| ANC-Emax | 21.285 ± 4.593 | 20.803 ± 4.097 | 20.726 ± 6.393 | 21.602 ± 5.93 |
Area Under Effect Curve (AUEC) "effect - time" from the moment of filgrastim injection to 336 hours based on CD-34 cells count (CD34)
| cell per microliter / hour | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| CD34-AUEC (0-336 Hours) | 1289 ± 762.292 | 1200.667 ± 761.29 | 1350.783 ± 716.645 | 1251.652 ± 562.087 |
Maximal absolute count of CD34-cells after single filgrastim injection
| cell per microliter | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| CD34-Emax | 7.694 ± 4.839 | 7.056 ± 5.248 | 9 ± 6.267 | 7.522 ± 4.22 |
| Participants | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| Overall Frequency of Serious Adverse Events (SAE) | 0 | 0 | 0 | 0 |
| Participants | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| Overall Frequency of Adverse Events (AE) | 36 | 35 | 22 | 22 |
| Participants | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| Frequency of Local Reactions | 0 | 0 | 0 | 0 |
Grading scale of CTCAE 4.03 Grade refers to the severity of the AE. The CTCAE displays Grades 1 through 5 with unique clinical descriptions of severity for each AE: Grade 1 Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated. Grade 2 Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental ADL (activities of daily living). Grade 3 Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL. Grade 4 Life-threatening consequences; urgent intervention indicated. Grade 5 Death related to AE.
| Participants | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| Frequency of AE/SAE 3-4 Grade CTCAE 4.03 | 0 | 1 | 0 | 0 |
| Participants | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| Frequency of Preliminary Withdrawal Due to AE/SAE | 0 | 0 | 0 | 0 |
Proportion of patients who had developed binding or neutralizing antibodies to filgrastim after single injection.
| Participants | Leucostim® Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim® Intravenous Injections | Neupogen® Intravenous Injections |
|---|---|---|---|---|
| Proportion of Patients With Binding or Neutralizing Antibodies to Filgrastim | 0 | 0 | 0 | 0 |
Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Leucostim®, Subcutaneous Injections | 0/36 (0%) | 0/36 (0%) | 36/36 (100%) |
| Neupogen® Subcutaneous Injections | 0/36 (0%) | 0/36 (0%) | 35/36 (97.2%) |
| Leucostim®, Intravenous Injections | 0/24 (0%) | 0/24 (0%) | 22/24 (91.7%) |
| Neupogen®, Intravenous Injections | 0/23 (0%) | 0/23 (0%) | 22/23 (95.7%) |
| Event | Leucostim®, Subcutaneous Injections | Neupogen® Subcutaneous Injections | Leucostim®, Intravenous Injections | Neupogen®, Intravenous Injections |
|---|---|---|---|---|
| MonocytosisBlood and lymphatic system disorders | 32/36 | 32/36 | 20/24 | 21/23 |
| eosinophiliaBlood and lymphatic system disorders | 10/36 | 15/36 | 9/24 | 7/23 |
| LymphocytosisBlood and lymphatic system disorders | 11/36 | 10/36 | 5/24 | 2/23 |
| head painNervous system disorders | 9/36 | 10/36 | 0/24 | 0/23 |
| Age, Continuous(years) | Leucostim® --> Neupogen®, Subcutaneous Injections | Neupogen® --> Leucostim®, Subcutaneous Injections | Leucostim® --> Neupogen®, Intravenous Injections | Neupogen® --> Leucostim®, Intravenous Injections | Total |
|---|---|---|---|---|---|
| Median | 22.94 (21.79 to 26.49) | 25.41 (22.45 to 29.58) | 23.48 (21.81 to 26.97) | 27.30 (24.61 to 27.78) | 24.63 (22.35 to 27.41) |
| Sex: Female, Male(Participants) | Leucostim® --> Neupogen®, Subcutaneous Injections | Neupogen® --> Leucostim®, Subcutaneous Injections | Leucostim® --> Neupogen®, Intravenous Injections | Neupogen® --> Leucostim®, Intravenous Injections | Total |
|---|---|---|---|---|---|
| Female | 0 | 0 | 0 | 0 | 0 |
| Male | 18 | 18 | 12 | 12 | 60 |
| Race and Ethnicity Not Collected(Participants) | Leucostim® --> Neupogen®, Subcutaneous Injections | Neupogen® --> Leucostim®, Subcutaneous Injections | Leucostim® --> Neupogen®, Intravenous Injections | Neupogen® --> Leucostim®, Intravenous Injections | Total |
|---|---|---|---|---|---|
| Count of participants | — | — | — | — | 0 |
No study locations are listed for this record.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Jul 2016 to primary completion in Nov 2016, 3 months.
Results were first posted in Dec 2018, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Filgrastim
Leukocytosis